Abstract Purpose of Review This review offers a critical narrative evaluation of emerging
evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective …

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the
availability of pharmacological treatments, both diseases remain associated with …

Accumulating evidence indicates that asymptomatic hyperuricemia is involved in the
development of hypertension and chronic kidney disease. A 2-hit model has been proposed …

Sodium‐glucose co‐transporter 2 inhibitors (SGLT2‐Is) have emerged as a promising class
of antidiabetic drugs with cardioprotective and renoprotective effects in patients with type 2 …

Background. Recent meta‐analyses have shown that sodium‐glucose cotransporter 2
(SGLT‐2) inhibitors alleviate chronic kidney disease and acute kidney injury in diabetic …

Results In the 18 trials with a total of 2051 AKI events (range: 1–300) among 156,690
patients with type 2 diabetes only, our network meta-analysis showed that SGLT2 inhibitors …

Introduction: The effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors on renal
outcomes in patients with chronic kidney disease (CKD) were initially demonstrated in …

Large clinical trials and real‐world studies have demonstrated that the beneficial effects of
sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on renal outcomes regardless of the …

Pharmacological agents used to treat or manage diseases can modify the level of heat strain
experienced by chronically ill and elderly patients via different mechanistic pathways …

Context SGLT2is are first-line antidiabetic agents with demonstrated cardiovascular benefits.
Prior meta-analyses have examined adverse events (AEs) associated with these drugs in …